SCHEMBL22323971

SCHEMBL22323971

COCOc1cc2c(=O)cc(C)oc2cc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.36
ACHE P22303 1/20 0.33
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGS1 P23219 6/20 0.32
PTGS2 P35354 6/20 0.32
CYP3A4 P08684 2/20 0.31
HPGD P15428 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CYP1A1 P04798 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
THRB P10828 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29380606 0.95 CSF1R (0.36) CSF1RACHEKDM4EMEN1MAPT
SCHEMBL22323706 0.95 CSF1R (0.36) CSF1RACHEKDM4EMEN1MAPT
SCHEMBL22323907 0.81 KDM4E (0.39) KDM4E
SCHEMBL24166096 0.76 KDM4E (0.40) CSF1RACHEKDM4EMEN1MAPT
SCHEMBL29380013 0.76 MAPK1 (0.40) ACHEKDM4EMEN1MAPTKMT2A
SCHEMBL22323724 0.76 MAPK1 (0.40) ACHEKDM4EMEN1MAPTKMT2A
SCHEMBL29447070 0.74 PDE10A (0.32) KDM4EMEN1MAPTKMT2AHPGD
SCHEMBL22324259 0.74 PDE10A (0.32) KDM4EMEN1MAPTKMT2AHPGD
SCHEMBL28705520 0.74 EGFR (0.33)
SCHEMBL22323948 0.74 PTGS1 (0.40) ACHEKDM4EMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192454-B1 AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES SKYHAWK THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 US disclosed
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-10-19 US disclosed
EP-4192454-A1 COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2023-06-14 EP disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
WO-2022031838-A1 COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2022-02-10 WO disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331718-A1 COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPE CSF1R 3108/4885ACHE 4723/4885KDM4E 2388/4885
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 CSF1R 3897/4885ACHE 4546/4885KDM4E 2530/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 CSF1R 3699/4885ACHE 4844/4885KDM4E 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.